Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what are the Health Data Research UK projects that access NHS data where specific project independent review was not received from NHS England's Advisory Group for Data, and what is the current status of those projects.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has a Data Sharing Agreement, project identification code DARS-NIC-381078-Y9C5K, with a consortium of academic organisations in the United Kingdom for the purpose of the Health Data Research UK-led, British Heart Foundation Data Science Centre’s CVD-COVID-UK programme.
This agreement was put in place by NHS Digital prior to its merger with NHS England in 2023, and prior to the establishment of NHS England’s Advisory Group for Data (AGD). The AGD was informed of a Senior Information Risk Owner decision to approve an amendment to the agreement on 22 February 2024.
The agreement was subject to reviews by NHS Digital’s Independent Group Advising on the Release of Data (IGARD) on 25 June 2020, 23 July 2020, 15 October 2020, 3 December 2020, 25 February 2021, 29 July 2021, 29 July 2021, 5 May 2022, and 24 November 2022. It was also subject to advice from the Professional Advisory Group on 24 June 2020 and 28 July 2021.
The agreement allowed the data controllers under that agreement to approve access to National Health Service data for individual projects, subject to approval per project by the CVD-COVID-UK oversight committee, which included a representative of NHS Digital/NHS England. Individual projects were not reviewed by IGARD or the AGD.
Under the terms of the agreement, the CVD-COVID-UK oversight committee is required to maintain a list of projects undertaken under the agreement and provide a quarterly report to NHS Digital/NHS England. The following table lists the projects and their current status from the latest report provided in April 2025:
Secure Data Environment research project reference | Current project status | Project title |
CCU001 | Live - Data in Use | Investigating the effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 outcomes |
CCU002 | Live - Data in Use | SARS-CoV-2 infection and vaccination and the risk of vascular events |
CCU003 | Live - Data in Use | Direct and indirect effects of the COVID-19 pandemic in individuals with cardiovascular disease (CVD) |
CCU004 | Live - Data in Use | COVID-19 and CVD risk prediction |
CCU005 | Live - Data in Use | Data management and analysis methods |
CCU007 | Live - Data in Use | Impact of COVID-19 pandemic on heart disease patients undergoing cardiac surgery |
CCU008 | Completed | Evaluating impact of COVID-19 pandemic on the prevalence and management of risk factors |
CCU010 | Live - Data in Use | In people with CVD and COVID-19, what is the influence of multi-morbidity on risk of poorer outcomes? |
CCU013 | Live - Data in Use | High-throughput electronic health record phenotyping approaches |
CCU014 | Live - Data in Use | Assessing the impact of COVID-19 on clinical pathways using a medicines approach |
CCU018 | Live - Data in Use | COVID-19 infection during pregnancy on CVD and related risk factors |
CCU019 | Live - Data in Use | Identification and personalised risk prediction for severe COVID-19 in patients with rare disorders impacting cardiovascular health |
CCU020 | Completed | Evaluation of antithrombotic use and COVID-19 outcomes |
CCU022 | Live - Data in Use | Genomics of multimorbidity and CVD associated with susceptibility to COVID-19 infection and complications |
CCU023 | Live - Data in Use | Repurposing medicines used to treat CVD risk to prevent COVID-19 |
CCU024 | Completed | CovPall-Connect. Evaluation of how palliative and end of life care teams have responded to COVID-19: Connecting to boost impact and data assets |
CCU028 | Live - Data in Use | Coronary revascularisation and outcomes before and after the COVID-19 pandemic |
CCU029 | Live - Data in Use | Child hospital admission with COVID-19: risk factors; risk groups; and NHS care utilisation |
CCU030 | Live - Data in Use | Examining potential factors underlying the increased risk of severe COVID-19 experienced by people with intellectual and developmental disabilities |
CCU032 | Live - Data in Use | The effects of COVID-19 on heart failure subtypes |
CCU035 | Completed | Are people with COVID-19 and pre-existing respiratory disease at a higher risk of future cardiovascular and venous thromboembolic events compared with COVID-19 patients without pre-existing respiratory disease? |
CCU036 | Live - Data in Use | The impact of previous exposure to COVID-19 and the safety of COVID-19 vaccination for fertility and pregnancy outcomes |
CCU037 | Live - Data in Use | Improving methods to minimise bias in ethnicity data for more representative and generalisable models, using CVD in COVID-19 as an example |
CCU038 | Live - Data in Use | Evaluating the impact of COVID-19 on critical care outcomes |
CCU040 | Completed | Investigating why some people with diabetes have a greater risk of becoming seriously unwell or dying with COVID-19 |
CCU043 | Live - Data in Use | Investigating new onset diabetes following COVID-19 infection |
CCU045 | Live - Data in Use | The impact of COVID-19 on heart failure epidemiology, quality of care and outcomes across primary and secondary care |
CCU046 | Live - Data in Use | Severe mental illness and receipt of acute cardiac care and mortality following myocardial infarction |
CCU049 | Live - Data in Use | Healthcare utilisation in individuals with Long COVID |
CCU051 | Completed | Un-vaccination and under-vaccination against SARS-CoV-2 in the UK |
CCU052 | Live - Data in Use | An observational retrospective cohort study describing the changing epidemiology pre, during and post COVID-19 of asthma, interstitial lung disease, and chronic obstructive pulmonary disease in England |
CCU053 | Live - Data in Use | Risks and benefits of treatment with SGLT2 inhibitors and the impact of intercurrent illness with COVID-19 |
CCU056 | Completed | Socio-demographic make-up of patients undergoing surgical and transcatheter aortic valve intervention in England and the impact of COVID-19 on this |
CCU057 | Live - Data in Use | Risks for mortality in people with severe mental illnesses during the COVID-19 pandemic |
CCU058 | Live - Data in Use | COVID-19 impact on the long-term outcomes of Improving Access to Psychological Therapies in people with long-term cardiovascular conditions |
CCU059 | Completed | Which combinations of multiple long-term conditions are associated with the greatest risk of hospital admission over the winter season, and to what extent does COVID-19 or influenza vaccination modify this risk? |
CCU060 | Live - Data in Use | Improving characterisation, prediction and intervention for COVID-19 and influenza-related morbidity and mortality |
CCU063 | Live - Data in Use | The effect of COVID-19 on maternal and paediatric health among individuals whose first language isn’t English and require an interpreter in England: from preconception to adolescence |
CCU064 | Live - Data in Use | Impact of COVID-19 clinical care pathway changes on gestational diabetes incidence and pregnancy outcomes in England |
CCU066 | Live - Data in Use | Changes in acute cardiac care of patients with reduced kidney function during the COVID-19 pandemic |
CCU068 | Completed | The impact of vaccination on the excess clinical risks of COVID-19 in patients with congenital heart disease |
CCU069 | Live - Data in Use | RARE-CVD-COVID: To understand COVID-19 impact on intersectional disparity in rare versus common cardiometabolic diseases: CVD and metabolic diseases, including diabetes |
CCU070 | Live - Data in Use | Supporting novel trial designs using healthcare systems data to mitigate the impact of COVID-19 on diabetes research |
CCU071 | Live - Data in Use | A regional approach for policy makers to tackle health inequalities in CVD and its risk factors |
CCU072 | Live - Data in Use | Influence of COVID-19 on British burden of CVD |
CCU073 | Live - Data in Use | Impact of COVID-19 on the association between Type 2 diabetes and incidence of CVD |
CCU074 | Live - Data in Use | Improving the accuracy, equity and efficiency of using healthcare systems data for recruitment to a clinical trial involving people with CVD and diabetes mellitus: a simulation study in the “Covid era” using the CVD‑COVID‑UK dataset |
CCU075 | Live - Data in Use | Impact of the COVID-19 pandemic on corticosteroid use and side effects in Takayasu arteritis and ANCA-associated vasculitis in England |
CCU076 | Live - Data in Use | The effect of COVID-19 infection on cardiovascular outcomes: an interaction analysis with environmental exposure |
CCU077 | Live - Data in Use | Risk assessment and long-term outcomes of acute coronary syndrome management strategy in cardio-oncology patients before and after the COVID-19 era |
CCU078 | On hold | Foresight: a generative artificial intelligence model of patient trajectories across the COVID-19 pandemic |
CCU079 | Live - Data in Use | Investigating the diagnoses of conditions among children in England following SARS-CoV-2 infections compared to general respiratory infections |
CCU080 | Live - Data in Use | Impact of COVID-19 on the use of cardiovascular imaging |
CCU081 | Live - Data in Use | Investigating the impact of COVID-19 on cardiovascular and thromboembolic events in idiopathic inflammatory myopathies and the incidence of connective tissue diseases |
CCU082 | Live - Data in Use | Pulmonary arterial hypertension in repaired congenital heart disease: impact of the COVID-19 pandemic on prevalence; late diagnosis; and outcomes |
CCU083 | Live - Data in Use | Trends in choice of management strategy for NSTE-ACS among patients with previous bypass surgery before and after the COVID-19 pandemic |
CCU084 | Live - Data in Use | Impact of COVID-19 on stroke incidence, severity, aetiology, management, and outcome in younger versus older individuals in England |
CCU085 | Live - Data in Use | STROKE-IMPACT: What are the long-term consequences of stroke on the patient and to the NHS, and how does COVID-19 contribute to variation? |
CCU086 | Live - Data in Use | A data landscape review of datasets used in the surveillance of neurological complications of COVID-19 |
CCU087 | Live - Data in Use | The impact of COVID-19 on heart failure outcomes: the moderation roles of diabetes and obesity |
CCU088 | Live - Data in Use | The impact of COVID-19 on the management of iron deficiency, with or without anaemia, in primary and secondary care |
CCU089 | Live - Data in Use | The impact of comorbidity, socioeconomic status, and ethnicity on waiting times for surgery before and after the COVID-19 pandemic |
CCU090 | Live - Data in Use | The impact of cardiac rehabilitation following transcatheter aortic valve implantation before and after the COVID-19 pandemic |
CCU092 | Live - Data in Use | Simulation modelling of CVD development and management, identifying the extent to which COVID-19 has impacted on the assessment and treatment of CVD. |
CCU093 | Live - Data in Use | Understanding the relationship between diabetes and the development of multiple long-term conditions in England, Scotland, and Wales during and after the COVID-19 pandemic |
CCU094 | Live - Data in Use | Identifying preventative opportunities for coronary heart disease and stroke in multi-ethnic patients with non-cardiovascular conditions including COVID-19 |
CCU095 | Live - Data in Use | Quantifying and mitigating bias and health inequalities induced by clinical risk models predicting COVID-19-related risks of people with CVD and diabetes. |
CCU096 | Live - Data in Use | Impact of COVID-19 on obesity and risks of cardio-renal-metabolic outcomes |
CCU097 | Live - Data in Use | Drivers, consequences and the COVID-19 pandemic’s effect on severe hyperglycaemia at type 2 diabetes diagnosis |
CCU100 | Live - Data in Use | Impact of COVID-19 on fatty liver disease and cardiovascular outcomes in England, across ethnicities and social deprivation |
CCU101 | Live - Data in Use | Lung-Pal-Equity: To identify patterns in use of hospital services in the last year of life for those with advanced lung disease and to examine inequalities by socio-economic group, including before, during and after the COVID-19 pandemic |
The status of project CCU078 has been updated to reflect that NHS England paused the project on 29 May. Further detail on the projects is published on the British Heart Foundation Data Science Centre’s website.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will make an assessment of the potential merits of an (a) centralised and (b) nationwide case-finding programme to identify people at high risk of (i) developing and (ii) inheriting less survivable cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Disease Registration Service (NDRS) has committed to developing a National Inherited Cancer Predisposition Register (NICPR) as part of its 2024 to 2027 strategy, building on the work to establish the National Lynch Registry. The NICPR will launch on 30 June, and will look at a wider range of cancers for which there is an increased inherited risk, including for less survivable cancers. It will identify high-risk individuals who are eligible for targeted screening and surveillance, and will act as an electronic referral route into national screening programmes where these exist, for instance Lynch syndrome and bowel screening.
The NICPR is also a key commitment in the Rare Disease Action Plan for England, with NDRS in NHS England as the lead delivery partner, further highlighting its relevance to improving care for people with rare inherited cancer risk.
NHS England is also working on case-finding approaches for less survivable cancers, where the evidence suggests this is appropriate. It is currently developing a public-facing Family History Checker, which enables people and their families affected by pancreatic cancer to self-assess if they may inherit risk. Individuals identified as being at risk are referred directly to the European Registry of Hereditary Pancreatic Diseases research trial, which aims to understand inherited conditions of the pancreas. Referrals to the trial can be made by any healthcare professional across all health sectors or by individuals via self-referral, contributing to a centralised approach to case-finding.
As part of our National Cancer Plan, we have been working with members of the Less Survivable Cancers Taskforce, a group of charities focusing on cancers with poor survival rates, to identify how we can improve diagnosis, treatment, and outcomes for less survivable cancers.
Asked by: David Davis (Conservative - Goole and Pocklington)
Question to the Home Office:
To ask the Secretary of State for the Home Department, how many technical capability notices her Department has issued under s.253 of the Investigatory Powers Act 2016 in each year, not including the notice rejected by Apple.
Answered by Dan Jarvis - Minister of State (Cabinet Office)
For reasons of national security, it has been a long-standing position that the Government does not confirm or deny compliance of operators given a notice under the Investigatory Powers Act 2016. We also do not publish the number of technical capability notices issued or release identities of those subject to a technical capability notice. To do so may identify operational capabilities or harm the commercial interests of companies.
Asked by: David Davis (Conservative - Goole and Pocklington)
Question to the Home Office:
To ask the Secretary of State for the Home Department, how many technical capability notices issued under s.253 of the Investigatory Powers Act 2016 have been complied with in each year.
Answered by Dan Jarvis - Minister of State (Cabinet Office)
For reasons of national security, it has been a long-standing position that the Government does not confirm or deny compliance of operators given a notice under the Investigatory Powers Act 2016. We also do not publish the number of technical capability notices issued or release identities of those subject to a technical capability notice. To do so may identify operational capabilities or harm the commercial interests of companies.
Asked by: Baroness Owen of Alderley Edge (Conservative - Life peer)
Question to the Home Office:
To ask His Majesty's Government what safeguards are in place to prevent access to intimate images when public authorities gain access to iCloud under the Investigatory Powers Act 2016.
Answered by Lord Hanson of Flint - Minister of State (Home Office)
The Home Office does not comment on operational matters, including for example confirming or denying the existence of any notices. This has been the longstanding position of successive UK Governments for reasons of national security.
The Investigatory Powers Act 2016 contains numerous safeguards including independent oversight, to ensure data is only requested on an exceptional basis and when strictly necessary and proportionate.
Asked by: Andrew Rosindell (Reform UK - Romford)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment he has made of the potential implications for his policies of recent changes in Canada's border security measures for UK citizens traveling to Canada.
Answered by Stephen Doughty - Minister of State (Foreign, Commonwealth and Development Office)
We have taken note of Canada's new border policies, which include expanded surveillance, heightened screening, and enhanced tools to detect fraud. We will continue to monitor any impact on British travellers.
UK citizens travelling to Canada should ensure they have an Electronic Travel Authorisation or visa as required, and they should ensure their passport is valid for the length of their stay. They should also consult FCDO Travel Advice, which is kept up to date with the latest requirements.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of restrictions on the use of electronic prescriptions for the issuing of medicinal cannabis products.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Rules around the electronic prescribing of cannabis-based medicines are no different to other drugs regulated in Schedule 2 to 5 of the Misuse of Drugs Regulations 2001.
In England, the NHS Electronic Prescription Service (EPS) enables the electronic transmission of prescriptions for Schedule 2 to 5 controlled drugs. As part of the robust system of governance and restrictions around the most addictive and harmful drugs, all private healthcare provider prescriptions for Schedule 2 and 3 controlled drugs cannot be transmitted by electronic means and must be issued on a paper FP10PCD prescription form. All paper copies of private prescriptions of Schedule 2 and 3 controlled drugs must be submitted to the NHS Business Services Authority. NHS England Controlled Drug Accountable Officers have a statutory duty to monitor the management and use of controlled drugs in the National Health Service and private healthcare.
Similar legislative and governance arrangements are in place in Northern Ireland concerning the management and use of controlled drugs. All private prescribing of Schedule 2 and 3 controlled drugs must be issued on a paper PCD1 prescription form, which, once dispensed, are submitted to the Business Services Organisation, in line with requirements in the Misuse of Drugs (Northern Ireland) Regulations 2002. There is currently no electronic transmission of prescriptions in primary care in Northern Ireland.
The Medicines and Healthcare products Regulatory Agency (MHRA) does not provide guidance on the use of medicinal cannabis. The MHRA provides guidance on manufacturing, importing, distributing, and supplying unlicensed medicines, which includes cannabis-based products for medicinal use in humans.
Current guidelines on the prescribing and use of cannabis-based medicinal products, specifically guideline NG144, are published on the National Institute for Health and Care Excellence website, which is available at the following link:
The guidelines have been endorsed by the Department of Health in Northern Ireland as applicable within Health and Social Care in Northern Ireland. The National Institute for Health and Care Excellence develops its guidance independently and keeps its published guidelines under active surveillance, so that it is able to update its recommendations in light of any significant new evidence.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the Medicines and Healthcare products Regulatory Agency guidance on the use of medicinal cannabis.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Rules around the electronic prescribing of cannabis-based medicines are no different to other drugs regulated in Schedule 2 to 5 of the Misuse of Drugs Regulations 2001.
In England, the NHS Electronic Prescription Service (EPS) enables the electronic transmission of prescriptions for Schedule 2 to 5 controlled drugs. As part of the robust system of governance and restrictions around the most addictive and harmful drugs, all private healthcare provider prescriptions for Schedule 2 and 3 controlled drugs cannot be transmitted by electronic means and must be issued on a paper FP10PCD prescription form. All paper copies of private prescriptions of Schedule 2 and 3 controlled drugs must be submitted to the NHS Business Services Authority. NHS England Controlled Drug Accountable Officers have a statutory duty to monitor the management and use of controlled drugs in the National Health Service and private healthcare.
Similar legislative and governance arrangements are in place in Northern Ireland concerning the management and use of controlled drugs. All private prescribing of Schedule 2 and 3 controlled drugs must be issued on a paper PCD1 prescription form, which, once dispensed, are submitted to the Business Services Organisation, in line with requirements in the Misuse of Drugs (Northern Ireland) Regulations 2002. There is currently no electronic transmission of prescriptions in primary care in Northern Ireland.
The Medicines and Healthcare products Regulatory Agency (MHRA) does not provide guidance on the use of medicinal cannabis. The MHRA provides guidance on manufacturing, importing, distributing, and supplying unlicensed medicines, which includes cannabis-based products for medicinal use in humans.
Current guidelines on the prescribing and use of cannabis-based medicinal products, specifically guideline NG144, are published on the National Institute for Health and Care Excellence website, which is available at the following link:
The guidelines have been endorsed by the Department of Health in Northern Ireland as applicable within Health and Social Care in Northern Ireland. The National Institute for Health and Care Excellence develops its guidance independently and keeps its published guidelines under active surveillance, so that it is able to update its recommendations in light of any significant new evidence.
Asked by: Colum Eastwood (Social Democratic & Labour Party - Foyle)
Question to the Home Office:
To ask the Secretary of State for the Home Department, whether her Department (a) received and (b) granted requests to provide communications data on (i) lawyers, (ii) journalists and (iii) Members of the Northern Ireland Assembly in each of the last five years.
Answered by Dan Jarvis - Minister of State (Cabinet Office)
The Investigatory Powers Commissioner's Office is the independent oversight body responsible for communications data authorisations.The most recent Information on the authorisation of investigatory powers, including the use of powers and number of authorisations obtained in relation to sensitive professions, is available in the Investigatory Powers Commissioner's Office Annual Report 2022 Annual Report of the Investigatory Powers Commissioner 2022 (ipco-wpmedia-prod-s3.s3.eu-west-2.amazonaws.com)
The use of covert investigatory powers is subject to strong safeguards and robust independent oversight by the Investigatory Powers Commissioner, and authorisations must be consistent with the law. The Investigatory Powers Act 2016 outlines specific additional protections in respect of journalistic material and sources, as well as items subject to legal privilege.
The government is unable to confirm nor deny the existence of any specific authorisations granted under the Investigatory Powers Act 2016 (IPA) or the Regulation of Investigatory Powers Act 2000 (RIPA).
Prior to March 2024 the Office for Communications Data Authorisations, headed by the Investigatory Power’s Commissioner, considered requests for communications data from law enforcement and public authorities. However, since March 2024, the Office for Communications Data Authorisations has become part of the Investigatory Powers Commissioner’s Office.
Asked by: Liam Byrne (Labour - Birmingham Hodge Hill and Solihull North)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, what recent assessment she has made of the effectiveness of export controls on cyber-surveillance tools.
Answered by Alan Mak
The UK already controls the export of a range of cyber-surveillance tools. Export licence applications for such items are rigorously assessed against the Strategic Export Licensing Criteria taking full account of risks to national security and human rights. The UK Government continues to work through the international export control regimes to ensure these controls remain up-to-date.
In assessing licences involving sensitive communications technology, the Export Control Joint Unit also takes advice from HM Government’s National Cyber Security Centre.